Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۹۹ • واحد: mm
حداقل ۰ — حداکثر ۱۰ • واحد: nodules
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Within Up-to-Seven Criteria0–7
- Beyond Up-to-Seven Criteria7–999
The Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival calculator is designed for bedside predicting 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting.
Clinical Guidelines & Evidence
Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.
Clinical Indication
The Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival is indicated for bedside clinical practice to support Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Up-to-Seven: Sum of largest tumor diameter (cm) + number of tumors ≤7. Survival prediction based on tumor characteristics matrix.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| largest_nodule_size | integer | Yes | Size of the largest vital tumor nodule in millimeters(mm) |
| number_of_nodules | integer | Yes | Number of vital tumor nodules (≥1cm)(nodules) |
| vascular_invasion | string | Yes | Presence or absence of vascular invasion |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–7 | Within Up-to-Seven Criteria | Sum of size (cm) + number ≤7, no vascular invasion |
| 7–999 | Beyond Up-to-Seven Criteria | Sum of size (cm) + number >7 or vascular invasion present |
Evidence-Based References (EBM)
- Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43.
- Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018 Jan;154(1):128-139.
- Lei JY, Wang WT, Yan LN. "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013 Nov 28;19(44):8093-8.